相关临床试验
1673
95 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1876
终止
173
10.3%
招募中
185
11.1%
暂停
3
0.2%
撤回
159
9.5%
进行中（未招募）
59
3.5%
Unknown
12
0.7%
已完成
1046
62.5%
Enrolling By Invitation
15
0.9%
尚未招募
21
1.3%
暂无批准数据
- A 20-year randomized controlled trial of 2,021 participants found that speed-of-processing brain training exercises reduced dementia risk by 25% compared to control groups. - Only speed training showed protective effects, while memory and reasoning exercises provided no significant reduction in Alzheimer's disease or dementia diagnoses. - The protective effect required just 10-24 hours of training spread over three years, with booster sessions enhancing the long-term benefits. - Results suggest speed training may upregulate acetylcholine production, a neurotransmitter critical for attention and brain plasticity that declines with age.
- Syngene International has formed a strategic collaboration with Johns Hopkins University to advance early-stage drug discovery programs and platform technologies from the university's research laboratories. - The partnership will utilize Syngene SynVent, a fully integrated drug discovery platform spanning discovery biology, medicinal chemistry, DMPK, toxicology, and early development services. - Syngene's Connector model will bridge high-potential early-stage assets with strategic investors and downstream partnerships to accelerate the translation of academic research into therapeutic candidates. - The collaboration aims to significantly compress development timelines and create a more efficient pipeline for bringing new medicines from laboratory discoveries to clinical relevance.
- Sun Pharma Advanced Research Company (SPARC) is implementing a major restructuring to achieve $10 million in annual cost savings while managing $46 million in debt and consolidating operations in Vadodara. - The company is reducing its workforce by 40% to 246 employees by FY27 and cutting R&D spending from $20.4 million to $14.3 million in FY25 while focusing on high-value oncology and immunology assets. - Lead oncology candidate SBO-154, an anti-MUC1-SEA antibody drug conjugate, is advancing through Phase 1a dose escalation targeting multiple cancer types with maximum tolerated dose readout expected by Q4 2026. - Immunology asset SCD-153, a first-in-class topical itaconate prodrug for alopecia areata and vitiligo, completed Phase 1b cohort 1 with topline results anticipated in Q4 2026.
- Northwestern Medicine and Scripps Health have enrolled their first patients in Aclarion's pivotal CLARITY trial, bringing the total number of active enrollment sites to four out of seven approved centers. - The multi-site trial aims to evaluate whether Nociscan technology can improve surgical outcomes beyond the current 54% industry benchmark for chronic low back pain surgery patients. - The company targets enrolling 25% of the planned 300 patients by Q2 2026, with initial interim data readout expected in Q3 2026 after the first cohort completes 3-month follow-up visits.
- KAIST researchers developed an AI model that predicts both T cell and B cell reactivity to neoantigens, overcoming limitations of current cancer vaccine approaches that focus primarily on T cell responses. - The AI platform analyzed over 437,000 peptides and 370 million B cell receptor sequences, demonstrating enhanced antitumor immune responses in preclinical studies and clinical trial analyses. - KAIST partnered with Neogenlogic to commercialize the technology, with plans to submit an FDA IND application and enter clinical trials by 2027. - Analysis of 11 personalized vaccine trials involving 1,739 neoantigens suggested that incorporating B cell neoepitopes may improve vaccination efficacy compared to T cell-only approaches.
- SereNeuro Therapeutics presented preclinical data at ISSCR showing SN101, a first-in-class iPSC-derived therapy that uses mature pain-sensing neurons to sequester inflammatory factors and relieve chronic osteoarthritis pain. - The novel "pain sponge" approach positions SN101 as a potential disease-modifying osteoarthritis drug (DMOAD) that halts cartilage degradation while providing non-addictive pain relief. - SN101 differs from conventional treatments by using fully mature, non-dividing cells that express all canonical pain receptors, enabling simultaneous modulation of multiple pain pathways without opioid addiction risks. - The Baltimore-based company, supported by Maryland Stem Cell Research Fund, is advancing toward IND-enabling studies for this counterintuitive therapeutic approach.
- Northwestern University scientists have developed the fastest hepatitis C diagnostic test yet, delivering results in just 15 minutes compared to 40-60 minutes for existing rapid tests. - Johns Hopkins University independently validated the test using 97 clinical specimens, confirming 100% agreement with commercial platforms. - The rapid point-of-care test could enable same-day diagnosis and treatment initiation, potentially supporting WHO's goal to eliminate hepatitis C by 2030. - The technology addresses a critical gap in hepatitis C care, as the infection affects 50 million people globally and causes 242,000 deaths annually despite being curable with medication.
- Cedars-Sinai researchers have developed TY1, the first "exomer" drug that repairs DNA damage and regenerates tissue without using stem cells, representing a breakthrough after two decades of research. - The synthetic RNA molecule enhances TREX1 gene activity to boost immune cells that clear damaged DNA, minimizing scar tissue formation after heart attacks and improving recovery outcomes. - TY1 shows therapeutic potential beyond cardiac applications, demonstrating efficacy in autoimmune diseases where the body attacks healthy tissue. - The drug is now advancing to clinical trials, potentially establishing a new class of therapeutics for treating tissue damage from heart attacks, inflammatory diseases, and other conditions.
- The FDA granted 510(k) clearance to Francis Medical's Vanquish Water Vapor System for prostate tissue ablation in patients with intermediate-risk prostate cancer on December 2, 2025. - Clinical data from the VAPOR 2 trial showed 91% of patients had no targeted MRI visible intermediate-risk disease at 6 months following a single procedure. - The treatment demonstrated low rates of urinary incontinence and erectile dysfunction, with 93% of patients reporting satisfaction at 12 months post-procedure. - The clearance enables commercial launch of this minimally invasive alternative to traditional prostate cancer treatments like surgery and radiation.
- Johns Hopkins University researchers have patented a new crystal form of mebendazole called polymorph C that demonstrates superior tumor penetration compared to standard formulations. - The enhanced formulation can effectively cross the blood-brain barrier and reach brain tumors at therapeutic concentrations, addressing a major challenge in treating brain cancers. - Preclinical studies in mice showed polymorph C achieved increased tumor suppression with acceptable toxicity across multiple cancer types including gliomas, breast, colon, and pancreatic cancers. - The 40-year safety profile of mebendazole could accelerate clinical development, potentially offering an affordable cancer therapy option for patients with deadly malignancies.
